FDA accepts Lucassin filing for hepatorenal syndrome
This article was originally published in Scrip
Executive Summary
The US FDA has accepted the final section of Orphan Therapeutics's NDA seeking approval of Lucassin (terlipressin) for the treatment of type 1 hepatorenal syndrome (HRS). The medicine has orphan drug status and fast track designation.